Streetbeat News

Regulatory

SPY

Fed Vice Chair Barr expressed disappointment with Q1 inflation, indicating it did not provide the confidence needed to ease monetary policy. The Fed will maintain tight policy for further time to observe its effects, and is in a good position to hold steady and monitor the economy. The current approach is deemed prudent to manage risks to both inflation and employment mandates.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:58 pm

BSFC

Trading halt status for Blue Star Foods Corp. (BSFC) was updated at 8:55:00 AM ET. The company has announced news and resumption times for trading.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:55 pm

DIST

Trading for DIST was halted at 8:55:00 a.m. ET due to pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:55 pm

ACB

CGC

SNDL

TLRY

The Department of Justice has initiated the formal rulemaking process to reclassify cannabis to Schedule III, which could positively impact cannabis stocks. However, immediate benefits for U.S. plant-touching stocks may be limited due to liquidity and regulatory issues. Key dates for the rescheduling process have been outlined, with potential final implementation around September 2024. Canadian cannabis companies like Canopy Growth Corporation, SNDL, Tilray Brands, and Aurora Cannabis may need to form partnerships with U.S. companies to capitalize on the changes.

Portfolio Pulse from Nicolás Jose Rodriguez

May 20, 2024 | 12:55 pm

ARCT

CSLLY

CSL and Arcturus Therapeutics announced that Nature Communications has published pivotal data demonstrating the efficacy and tolerability of their self-amplifying (sa-mRNA) COVID-19 vaccine, ARCT-154. The data shows superior immunogenicity to Omicron BA 4/5 and longer duration of immunity compared to traditional mRNA COVID-19 vaccine boosters.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:42 pm

DYN

NKGN

PTCT

Market-Moving News for May 20th includes significant updates from PTC Therapeutics, NKGen Biotech, and Dyne Therapeutics. PTC Therapeutics' Translarna is up for re-evaluation by the European Commission. NKGen Biotech's SNK01 has been cleared for Phase 2 development in Alzheimer's Disease. Dyne Therapeutics shared clinical data from its ongoing trials for DYNE-101 and DYNE-251.

Portfolio Pulse from ryanfaloona@benzinga.com

May 20, 2024 | 12:38 pm

LSTA

Lisata Therapeutics has reached an agreement with the European Medicines Agency (EMA) on a Paediatric Investigation Plan for its lead product, Certepetide, in pancreatic cancer. The company has also received a full pediatric waiver.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:35 pm

LSTA

The European Medicines Agency (EMA) has granted Lisata Therapeutics a waiver for paediatric investigation plans for their drug, certepetide, in pancreatic cancer. This waiver means that paediatric studies are not required, thereby avoiding significant clinical trial burdens and costs.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:31 pm

JKS

JinkoSolar Holdings' 2000-Volt Module has received UL Certification and will be selectively deployed in the U.S. in Q3 2024, with general market availability in 2025.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:30 pm

PTCT

PTC Therapeutics shares are trading higher following the announcement that the European Commission has returned the Translarna opinion to the CHMP for re-evaluation.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:22 pm